PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+30.71%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$4.66B
AUM Growth
+$4.66B
(+12%)
Cap. Flow
-$219M
Cap. Flow
% of AUM
-4.69%
Top 10 Holdings %
Top 10 Hldgs %
46.73%
Holding
123
New
13
Increased
23
Reduced
25
Closed
18
Top Buys
| 1 |
VRNA
Verona Pharma
VRNA
|
$112M |
| 2 |
Viking Therapeutics
VKTX
|
$62M |
| 3 |
argenx
ARGX
|
$56M |
| 4 |
Nuvalent
NUVL
|
$44M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$37.6M |
Top Sells
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$441M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
$74.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
$50.4M |
| 4 |
Natera
NTRA
|
$39.4M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$38.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.85B
| $325M | 6.87% | 3,888,669 -1,070 | -0% | -$89.4K |
|
|
2
Nuvalent
NUVL
$5.52B
| $305M | 6.45% | 2,979,235 +430,158 | +17% | +$44M |
|
3
Amicus Therapeutics
FOLD
$2.34B
| $300M | 6.34% | 28,057,456 | – | – |
|
4
Iovance Biotherapeutics
IOVA
$807M
| $250M | 5.29% | 26,617,709 +684,567 | +3% | +$6.43M |
|
5
Vaxcyte
PCVX
$4B
| $232M | 4.9% | 2,027,608 +165,000 | +9% | +$18.9M |
|
6
Rhythm Pharmaceuticals
RYTM
$6.85B
| $187M | 3.95% | 3,560,214 +113,635 | +3% | +$5.95M |
|
|
VRNA
7
Verona Pharma
VRNA
$9.16B
| $182M | 3.84% | 6,315,933 +3,882,208 | +160% | +$112M |
|
8
Soleno Therapeutics
SLNO
$3.6B
| $162M | 3.42% | 3,204,976 | – | – |
|
|
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $119M | 2.51% | 1,622,215 -94,192 | -5% | -$6.89M |
|
10
Apogee Therapeutics
APGE
$2.17B
| $118M | 2.5% | 2,015,007 -90,629 | -4% | -$5.32M |
|
|
11
Viking Therapeutics
VKTX
$3.04B
| $108M | 2.28% | 1,699,987 +978,610 | +136% | +$62M |
|
|
CNTA
12
Centessa Pharmaceuticals
CNTA
$2.25B
| $100M | 2.13% | 6,282,290 +2,348,983 | +60% | +$37.6M |
|
13
Immatics
IMTX
$619M
| $92.3M | 1.95% | 8,086,159 | – | – |
|
14
Evolus
EOLS
$494M
| $86.8M | 1.84% | 5,356,622 -397,176 | -7% | -$6.43M |
|
15
Spyre Therapeutics
SYRE
$996M
| $84.5M | 1.79% | 2,872,547 -158,471 | -5% | -$4.66M |
|
16
Artivion
AORT
$2.07B
| $74.4M | 1.57% | 2,793,703 | – | – |
|
17
Biohaven
BHVN
$1.63B
| $74.2M | 1.57% | 1,485,232 | – | – |
|
18
Astria Therapeutics
ATXS
$349M
| $71.4M | 1.51% | 6,485,420 | – | – |
|
19
Axsome Therapeutics
AXSM
$6.05B
| $70.4M | 1.49% | 782,844 +323,733 | +71% | +$29.1M |
|
20
Applied Therapeutics
APLT
$71M
| $68M | 1.44% | 8,005,000 | – | – |
|
|
CRGX
21
DELISTED
CARGO Therapeutics
CRGX
| $68M | 1.44% | 3,683,004 | – | – |
|
22
Immunovant
IMVT
$2.56B
| $67.8M | 1.43% | 2,378,762 +454,976 | +24% | +$13M |
|
23
Praxis Precision Medicines
PRAX
$958M
| $67M | 1.42% | 1,164,035 +413,805 | +55% | +$23.8M |
|
|
24
argenx
ARGX
$43.6B
| $64.4M | 1.36% | 118,839 +103,239 | +662% | +$56M |
|
25
Viridian Therapeutics
VRDN
$1.5B
| $64M | 1.35% | 2,812,665 +1,180,837 | +72% | +$26.9M |
|